Novartis will halt its rocky commercialization partnership with Amgen for the migraine treatment, Aimovig, laying off employees that have been working on the drug.Original Article
You may also like
Nouscom to present re‑treatment data in Lynch...
ViiV Healthcare to unveil new HIV treatment data at...
Almirall’s paediatric registration of Ebglyss for...
The Bloc appoints Jon Chapman as European Executive...
Flu Virus Interaction with Host Cell Machinery Mapped...
UCSD, IGI Partnership Expands CRISPR Innovation Across...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.